approval
saveLIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
community read0 votes
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INTRAVENOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 2 completionRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)Apr 30, 2026 · 157d ago
- phase 1 completionOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)Apr 30, 2026 · 157d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 29, 2025 · 340d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 8, 2025 · 361d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 5, 2024 · 912d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1255d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1255d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalNov 8, 2022 · 1426d ago
same company · ±60 days · 5
- approvalalirocumab: PRALUENT (ALIROCUMAB) — FDA approvalMar 8, 2024
- approvalcemiplimab: LIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 5, 2024
- approvaldupilumab: DUPIXENT (DUPILUMAB) — FDA approvalApr 12, 2024
- approvaldupilumab: DUPIXENT (DUPILUMAB) — FDA approvalJan 25, 2024
- approvaldupilumab: DUPIXENT (DUPILUMAB) — FDA approvalJan 12, 2024
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 15 sources
- drugLIBTAYO60 co-mentions · 15 sources
- tagOncology12 co-mentions · 3 sources
- tagPulmonology4 co-mentions · 1 sources
- tagNSCLC3 co-mentions · 1 sources
- tagBreast Cancer3 co-mentions · 1 sources
- tagMelanoma3 co-mentions · 1 sources
- tagColorectal Cancer2 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that